DARE vs. VTGN, REPH, ABEO, GTHX, GLSI, GALT, RNAC, RZLT, ALIM, and RIGL
Should you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Vistagen Therapeutics (VTGN), Recro Pharma (REPH), Abeona Therapeutics (ABEO), G1 Therapeutics (GTHX), Greenwich LifeSciences (GLSI), Galectin Therapeutics (GALT), Cartesian Therapeutics (RNAC), Rezolute (RZLT), Alimera Sciences (ALIM), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "medical" sector.
Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking.
78.4% of Vistagen Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are held by institutional investors. 1.0% of Vistagen Therapeutics shares are held by company insiders. Comparatively, 4.0% of Daré Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Daré Bioscience had 1 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 3 mentions for Daré Bioscience and 2 mentions for Vistagen Therapeutics. Daré Bioscience's average media sentiment score of 0.94 beat Vistagen Therapeutics' score of 0.42 indicating that Vistagen Therapeutics is being referred to more favorably in the media.
Vistagen Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
Vistagen Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 392.23%. Daré Bioscience has a consensus price target of $4.50, suggesting a potential upside of 997.56%. Given Vistagen Therapeutics' higher possible upside, analysts plainly believe Daré Bioscience is more favorable than Vistagen Therapeutics.
Daré Bioscience has a net margin of 0.00% compared to Daré Bioscience's net margin of -3,073.51%. Daré Bioscience's return on equity of -72.10% beat Vistagen Therapeutics' return on equity.
Daré Bioscience received 73 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. Likewise, 73.29% of users gave Daré Bioscience an outperform vote while only 72.24% of users gave Vistagen Therapeutics an outperform vote.
Daré Bioscience has higher revenue and earnings than Vistagen Therapeutics.
Summary
Daré Bioscience beats Vistagen Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Daré Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Daré Bioscience Competitors List
Related Companies and Tools
